Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Avaliv |
Description | Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic OK ABOUT US TEAM ADVISORY BOARD SCIENCE CONTACT Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic steatohepatitis ( |
Keywords | N/A |
WebSite | avaliv.com |
Host IP | 103.120.177.134 |
Location | - |
Site | Rank |
US$1,911
Last updated: 2022-06-18 22:03:08
avaliv.com has Semrush global rank of 0. avaliv.com has an estimated worth of US$ 1,911, based on its estimated Ads revenue. avaliv.com receives approximately 220 unique visitors each day. Its web server is located in -, with IP address 103.120.177.134. According to SiteAdvisor, avaliv.com is safe to visit. |
Purchase/Sale Value | US$1,911 |
Daily Ads Revenue | US$1 |
Monthly Ads Revenue | US$52 |
Yearly Ads Revenue | US$635 |
Daily Unique Visitors | 14 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
avaliv.com. | A | 3599 | IP: 103.120.177.134 |
avaliv.com. | NS | 86400 | NS Record: ns2.digital24x7.com. |
avaliv.com. | NS | 86400 | NS Record: ns1.digital24x7.com. |
avaliv.com. | MX | 3600 | MX Record: 10 alt4.aspmx.l.google.com. |
avaliv.com. | MX | 3600 | MX Record: 5 alt1.aspmx.l.google.com. |
avaliv.com. | MX | 3600 | MX Record: 10 alt3.aspmx.l.google.com. |
avaliv.com. | MX | 3600 | MX Record: 1 aspmx.l.google.com. |
avaliv.com. | MX | 3600 | MX Record: 5 alt2.aspmx.l.google.com. |
avaliv.com. | TXT | 3600 | TXT Record: v=spf1 a mx mx:avaliv.com ip4:103.120.177.134 ~all |
OK ABOUT US TEAM ADVISORY BOARD SCIENCE CONTACT Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic steatohepatitis (NASH) Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic steatohepatitis (NASH) Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic steatohepatitis (NASH) Developing first-in-class small molecule therapeutics for inflammation and non-alcoholic steatohepatitis (NASH) --> ABOUT US Avaliv Therapeutics is a drug discovery company focused on the development of novel small molecule therapeutics targeting inflammation and fibrosis related disorders. Our lead program is a first-in-class small molecule inhibitor for lysosomal proteases as a novel therapeutic intervention for non-alcoholic steatohepatitis (NASH) via an unexplored mechanistic pathway. MANAGEMENT TEAM --> Mr. Arun B Papaiah Founder and Chief Executive Officer Dr. Aditya Kulkarni Founder and Chief |
HTTP/1.1 301 Moved Permanently Date: Fri, 22 Oct 2021 17:21:37 GMT Server: Apache Location: https://avaliv.com/ Content-Type: text/html; charset=iso-8859-1 HTTP/1.1 301 Moved Permanently Date: Fri, 22 Oct 2021 17:21:38 GMT Server: Apache Location: https://www.avaliv.com/ Content-Type: text/html; charset=iso-8859-1 HTTP/1.1 200 OK Date: Fri, 22 Oct 2021 17:21:40 GMT Server: Apache Last-Modified: Fri, 25 May 2018 08:22:51 GMT ETag: "6167-56d03794d6cc0" Accept-Ranges: bytes Content-Length: 24935 Vary: Accept-Encoding Content-Type: text/html; charset=UTF-8 |
Domain Name: AVALIV.COM Registry Domain ID: 2173350601_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2020-09-14T02:38:34Z Creation Date: 2017-10-12T14:26:59Z Registry Expiry Date: 2021-10-12T14:26:59Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS1.DIGITAL24X7.COM Name Server: NS2.DIGITAL24X7.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-11T07:35:53Z <<< |